Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial

Addiction

Volumn 109, Issue 1, 2014, Pages 79-87

  Hser, Yih Ing ^a   Saxon, Andrew J ^b   Huang, David ^a   Hasson, Al ^a   Thomas, Christie ^a   Hillhouse, Maureen ^a   Jacobs, Petra ^c   Teruya, Cheryl ^a   Mclaughlin, Paul ^d   Wiest, Katharina ^e   Cohen, Allan ^f   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d Hartford Dispensary ^*  (United States)

^e CODA Inc ^*  (United States)

^f Bay Area Addiction Research and Treatment   (United States)

Author keywords

Buprenorphine; Methadone; Opiate dependence; Treatment outcomes

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADOLESCENT; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; BUPRENORPHINE, NALOXONE DRUG COMBINATION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890219309     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12333     Document Type: Article

References (35)

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: SAMHSA; 2011.
2. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55-70.
3. Warner M., Chen L. H., Makuc D. M., Anderson R. N., Miniño A. M. Drug Poisoning Deaths in the United States, 1980-2008. Hyattsville, MD: National Center for Health Statistics; 2011.
4. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. J. etal. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171, iii-iv.
5. Bell J., Trinh L., Butler B., Randall D., Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104: 1193-1200.
6. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 16(2): CD002207.
7. Pinto H., Maskrey V., Swift L., Rumball D., Wagle A., Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010; 39: 340-352.
8. Gerstein D. R., Harwood H. J., editors. Treating Drug Problems, vol. 1. Washington, DC: National Academy Press; 1990.
9. Walsh S. L., June H. L., Schuh K. J., Preston K. L., Bigelow G. E., Stitzer M. L. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995; 119: 268-276.
10. Awgu E., Magura S., Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. J Psychoact Drugs 2010; 42: 339-346.
11. Strain E. C., Harrison J. A., Bigelow G. E. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011; 89: 443-449.
12. Fareed A., Vayalapalli S., Casarella J., Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis 2012; 31: 8-18.
13. Saxon A. J., Ling W., Hillhouse M., Thomas C., Hasson A., Ang A. etal. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128: 71-76.
14. Ware J. E., Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
15. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Cox D. R. Regression models and life tables (with discussion). J R Stat Soc 1972; B34: 187-220.
17. Zeger S. L., Liang K. Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
18. SAS Institute, Inc. SAS/STAT User's Guide, Version 9.2. Cary, NC: SAS Institute, Inc.; 2009.
19. Jones H. E., Kaltenback K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
20. Epstein D. H., Preston K. L. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003; 98: 269-279.
21. Di Petta G., Leonardi C. Buprenorphine high-dose, broad spectrum, long-term treatment: a new clinical approach to opiate alkaloid dependency. Heroin Add Rel Clin Probl 2005; 7: 21-26.
22. Mégarbane B., Hreiche R., Pirnay S., Marie N., Baud F. J. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 2006; 25: 79-85.
23. Walsh S. L., Preston K. L., Stitzer M. L., Cone E. J., Bigelow G. E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-580.
24. Kress H. G. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13: 219-230.
25. Zubieta J., Greenwald M. K., Lombardi U., Woods J. H., Kilbourn M. R., Jewett D. M. etal. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000; 23: 326-334.
26. Greenwald M. K., Johanson C. E., Moody D. E., Woods J. H., Kilbourn M. R., Koeppe R. A. etal. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003; 28: 2000-2009.
27. Stimmel B. Buprenorphine misuse, abuse, and diversion: when will we ever learn? J Addict Dis 2007; 26: 1-3.
28. Johanson C. E., Arfken C. L., di Menza S., Schuster C. R. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012; 120: 190-195.
29. Strain E. C., Bigelow G. E., Liebson I. A., Stitzer M. L. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281: 1000-1005.
30. Fiellin D. A., Pantalon M. V., Chawarski M. C., Moore B. A., Sullivan Y. E., O'Connor P. G. etal. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355: 365-374.
31. Weiss R. D., Potter J. S., Fiellin D. A., Byrne M., Connery H. S., Dickinson W. etal. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011; 68: 1238-1246.
32. Ling W., Hillhouse M., Ang A., Jenkins J., Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 2013; 108: 1788-1798.
33. Kakko J., Gronbladh L., Svanborg K. D., von Wachenfeldt J., Ruck C., Rawlings B. etal. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007; 164: 797-803.
34. Peirce J. M., Petry N. M., Stitzer M. L., Blaine J., Kellogg S., Satterfield F. etal. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry 2006; 63: 201-208.
35. Haasen C., Verthein U., Degkwitz P., Berger J., Krausz M., Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2007; 191: 55-62.